万基遗传 MYGN 深 沪
等待开盘 02-04 09:30:00 美东时间
5.34
-0.130
-2.38%
华盛通- 最 高5.70
- 今 开5.46
- 成交量 102.15万股
- 最 低 5.32
- 昨 收 5.47
- 总市值 4.98亿
- 52周最高 15.47
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 3.76
- 委 比 12.45%
- 总股本 9321.37万
- 历史最高 50.44
- 量 比 1.41
- 振 幅 6.95%
- 历史最低 3.76
- 每 手 1
- 风险率 2.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Myriad Genetics Unveils 2026 Commercial Launch Of Precise MRD Assay, Highlighting Ultrasensitive ctDNA Detection Across Multiple Cancer Types
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and
01-27 21:51
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Myriad Genetics will launch Precise MRD, an ultrasensitive ctDNA assay, for breast cancer in March 2026, followed by colorectal and renal cancers later this year, with potential expansion to other cancer types in 2027 and beyond. The assay detects ctDNA at levels as low as one part per million, demonstrating high sensitivity and accurate recurrence prediction. Preliminary data from studies like MONITOR-Breast and MONSTAR-SCREEN-3 highlight the as...
01-27 13:50
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Myriad Genetics announced preliminary Q4 and full-year 2025 financial results, with Q4 revenues projected at $207-209M and full-year revenues at $822-824M. The company provided 2026 financial guidance, expecting revenues of $860-880M, an increase of approximately 6% compared to the 2025 mid-point. Adjusted gross margin is projected at 68-69%, reflecting new product launches, while adjusted EBITDA is expected to grow 43% to $37-49M. These figures ...
01-12 13:30
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that President and CEO Sam Raha will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 14 at 5:15 pm PT (8:15 pm ET). The presentation will be available via live webcast and archived at investor.myriad.com. Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focused on improving health outcomes and reducing healthcare costs through m...
01-05 21:15
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
Myriad Genetics will present new data on its Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test at the 2025 San Antonio Breast Cancer Symposium. The Precise MRD Test, an ultrasensitive, second-generation pan-tumor MRD test, is particularly impactful for low-tumor-shedding cancers like breast cancer. The MyRisk Test has been expanded to include genes referenced in NCCN Guidelines and ASCO guidelines, supporting guide...
2025-12-09 14:00
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
Clairity, Myriad Genetics, and MagView have formed a collaboration to improve breast cancer risk assessment by integrating genotype (Myriad’s MyRisk with RiskScore) and phenotype (Clairity Breast) data through MagView’s Luminary Risk platform. This partnership aims to better identify high-risk women without adding administrative burdens, offering a comprehensive and actionable risk view using AI-powered tools.
2025-11-25 21:15
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
2025-11-12 11:43
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, a leader in molecular diagnostics and precision medicine, announced that its management will participate in two upcoming healthcare conferences: the 7th Annual Wolfe Research Healthcare Conference on November 18, 2025, and the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025. Both events will include fireside chats available via live audio webcast on the investor information section of Myriad’s website.
2025-11-11 14:00
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
